1 |
Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
DOI
|
2 |
Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. Respirology 2006;11:6-17.
DOI
|
3 |
Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005;258:199-215.
DOI
|
4 |
Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. Heart Fail Rev 2013;18:607-22.
DOI
|
5 |
Kwong JQ, Molkentin JD. Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 2015;21:206-14.
DOI
|
6 |
Haworth RA, Hunter DR. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys 1979;195:460-7.
DOI
|
7 |
Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009;46:821-31.
DOI
|
8 |
Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore activated by Ca2+, inorganic phosphate and oxidative stress. A potential mechanism for mitochondrial dysfunction during cellular Ca2+ overload. Eur J Biochem 1988;178:489-501.
DOI
|
9 |
Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-8.
DOI
|
10 |
Sheu JJ, Chua S, Sun CK, et al. Intra-coronary administration of cyclosporine limits infarct size, attenuates remodeling and preserves left ventricular function in porcine acute anterior infarction. Int J Cardiol 2011;147:79-87.
DOI
|
11 |
Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012;165:1235-45.
DOI
|
12 |
Lim SY, Hausenloy DJ, Arjun S, et al. Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. J Cell Mol Med 2011;15:2443-51.
DOI
|
13 |
Bach PH, Lock EA. Nephrotoxicity: In Vitro and in Vivo, Animals to Man. 1st ed. New York (NY): Springer Science and Business Media; 2013. p.707.
|
14 |
Voelkel NF, Natarajan R, Drake JI, Bogaard HJ. Right ventricle in pulmonary hypertension. Compr Physiol 2011;1:525-40.
|
15 |
Daicho T, Yagi T, Abe Y, et al. Possible involvement of mitochondrial energy-producing ability in the development of right ventricular failure in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Sci 2009;111:33-43.
DOI
|
16 |
Hong YM, Kwon JH, Choi S, Kim KC. Apoptosis and inflammation associated gene expressions in monocrotaline-induced pulmonary hypertensive rats after bosentan treatment. Korean Circ J 2014;44:97-104.
DOI
|
17 |
Campian ME, Verberne HJ, Hardziyenka M, et al. Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med 2009;50:1371-7.
DOI
|
18 |
Zuo XR, Wang Q, Cao Q, et al. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PLoS One 2012;7:e44485.
DOI
|
19 |
Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 2011;1813:616-22.
DOI
|
20 |
Zungu-Edmondson M, Shults NV, Wong CM, Suzuki YJ. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Cardiovasc Res 2016;110:30-9.
DOI
|
21 |
Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96.
DOI
|
22 |
Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol 2015;78:129-41.
DOI
|
23 |
Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434:658-62.
DOI
|
24 |
Ramachandran A, Lebofsky M, Baines CP, Lemasters JJ, Jaeschke H. Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. Free Radic Res 2011;45:156-64.
DOI
|
25 |
Lim WY, Messow CM, Berry C. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br J Pharmacol 2012;165:2034-43.
DOI
|
26 |
Gomez L, Li B, Mewton N, et al. Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res 2009;83:226-33.
DOI
|
27 |
Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81.
DOI
|
28 |
Ghaffari S, Kazemi B, Toluey M, Sepehrvand N. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther 2013;31:e34-9.
DOI
|